



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

Date: 17.05.2024

To,  
National Stock Exchange of India Ltd. (NSE Ltd)  
Exchange Plaza, 05<sup>th</sup> Floor,  
Plot No. C-1, Block G,  
Bandra Kurla complex,  
Bandra (E) Mumbai – 400051

NSE Scrip Code - AJOONI

**Subject: Filing of Pre-Issue Advertisement pursuant to the proposed Rights Issue of Equity Shares of Ajooni Biotech Limited ("Company")**

Dear Sir / Madam,

We are submitting herewith copies of pre issue advertisement published in connection with Rights Issue of the Company. It has been published in the following newspapers:

1. Financial Express - English Daily (all editions);
2. Jansatta - Hindi Daily (all editions); and
3. Desh Sewak (Punjab Edition).

We are submitting the e-clipping copies of the said newspapers.

Kindly take this in your records.

Thanks & Regards,

For AJOONI BIOTECH LIMITED

JASJOT  
SINGH

Digitally signed  
by JASJOT SINGH  
Date: 2024.05.17  
12:29:34 +05'30'

Jasjot Singh  
Managing Director  
DIN: 01937631

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of offer dated 7<sup>th</sup> May, 2024 the "Letter of Offer" or ("LOF") filed with the National Stock Exchange of India Limited ("NSE"), and the Securities and Exchange Board of India ("SEBI").



# AJOONI BIOTECH LIMITED

(CIN-L85190PB2010PLC040162)

Our Company was originally incorporated at Chandigarh "Ajooni Biotech Private Limited" on 17<sup>th</sup> February, 2010 under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Consequent upon the conversion of our Company to public limited company, the name of our Company was changed to "Ajooni Biotech Limited" and fresh certificate of incorporation dated 27<sup>th</sup> September, 2017 was issued by the Registrar of Companies, Chandigarh, Punjab. For further details in relation to the changes to the name of our Company, please refer to the section titled "General Information" beginning on page 47 of this Letter of offer.

**Registered Office:** D-118, Industrial Area, Phase-7, Mohali Punjab -160055, **Tel:** +0172-5020758-69, **Email Id:** [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com), **Website:** [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

**Contact Person:** Mrs. Swati Vujan, Company Secretary & Compliance Officer

## PROMOTERS OF OUR COMPANY: MR. JASJOT SINGH AND M/S HEALTHY BIOSCIENCES LIMITED

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF AJOONI BIOTECH LIMITED ONLY NEITHER OUR COMPANY, OUR PROMOTERS NOR OUR DIRECTORS HAVE BEEN DECLARED AS A WILFUL DEFAULTER OR FRAUDULENT BORROWER BY THE RBI OR ANY OTHER GOVERNMENT AUTHORITY.

### THE ISSUE

ISSUE OF UPTO 8,76,13,721 EQUITY SHARES OF FACE VALUE OF RS. 2 EACH ("EQUITY SHARES") OF AJOONI BIOTECH LIMITED ("ABL" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 5.00 PER EQUITY SHARE (INCLUDING PREMIUM OF RS. 3.00 PER EQUITY SHARE) ("ISSUE PRICE") FOR AN AGGREGATE AMOUNT NOT EXCEEDING RS. 4,380.69 LACS TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. 7<sup>TH</sup> MAY, 2024 (THE "ISSUE"). THE ISSUE PRICE IS 2.50 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 115 OF THIS LETTER OF OFFER.

### ISSUE PROGRAMME

ISSUE OPENS ON	LAST DATE OF MARKET RENUNCIATIONS*	ISSUE CLOSURES ON**
TUESDAY, 21 <sup>ST</sup> MAY, 2024	MONDAY, 27 <sup>TH</sup> MAY, 2024	FRIDAY, 31 <sup>ST</sup> MAY, 2024

\*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.  
\*\*Our Board or a Rights Issue committee thereof will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

**ASBA\*** Simple, Safe, Smart way of Application - Make use of it!!!  
\*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below.

In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/CIR/CFD/DIL/67/2020 dated April 21, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/78 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/136 dated July 24, 2020 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2021/633 dated 01 October 2021 (Collectively hereafter referred to as "SEBI Rights Issue Circulars") and SEBI circular SEBI/CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL/1/2011 dated April 29, 2011 and the SEBI circular, bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022 (Collectively hereafter referred to as "ASBA Circulars"), all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Making of an Application through the ASBA Process" on page 118 of the Letter of Offer.

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialised form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two Working Days prior to the Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shares in physical form, and whose demat account details are not available with our Company or the Registrar, shall be credited in a demat suspense escrow account opened by our Company.

Please note that if Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date, have not provided the details of their demat accounts to our Company or to the Registrar, they are required to provide their demat account details to our Company or the Registrar not later than two Working Days prior to the Issue Closing Date, i.e., 29<sup>th</sup> May, 2024 to enable the credit of the Rights Entitlements by way of transfer from the demat suspense escrow account to their respective demat accounts, at least one day before the Issue Closing Date, i.e., 30<sup>th</sup> May, 2024.

**PROCEDURE FOR APPLICATION:** In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars and the ASBA Circulars, all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details of procedure for application by the resident Eligible Equity Shareholders holding Equity Shares in physical form as on the Record Date i.e., 7<sup>th</sup> May, 2024, see "Procedure for Application by Eligible Equity Shareholders holding Equity Shares in physical form" on page 121 of the Letter of Offer.

**PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS:** Shareholders, wishing to participate in this Issue through the ASBA facility, is required to have an ASBA enabled bank account with an SCSB, prior to making the Application. Shareholders desiring to make an Application in this Issue through ASBA process, may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/ electronic Application through the website of the SCSBs (if made available by such SCSB) for authorizing such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

**Self-Certified Syndicate Banks:**

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?do=Recognised&Fpl=yes&intmid=34>.

**APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARES IN PHYSICAL FORM:** Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialised form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two Working Days prior to the Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

**ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM: PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE, I.E. 07<sup>TH</sup> MAY, 2024.**

**DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM:** The Dispatch of the ALOF and Application Form for the Issue was completed on 14<sup>th</sup> May, 2024 by the Registrar to the Issue.

**CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS:** In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "AJOONI BIOTECH LIMITED SUSPENSE ESCROW DEMAT ACCOUNT") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or suspended for debit or credit or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI Listing Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two Working Days prior to the Issue Closing Date, i.e., by 29<sup>th</sup> May, 2024 to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in this Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar account is active to facilitate the aforementioned transfer.

**APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS:** The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- (a) Name of our Company, being Ajooni Biotech Limited;
- (b) Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);
- (c) Folio Number (in case of Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) DP and Client ID;
- (d) Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to this Issue
- (e) Number of Equity Shares held as on Record Date;
- (f) Allotment option – only dematerialised form;
- (g) Number of Equity Shares entitled to;
- (h) Number of Equity Shares applied for within the Rights Entitlements;
- (i) Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- (j) Total number of Equity Shares applied for;
- (k) Total amount paid at the rate of Rs. 5/- per Equity Share;
- (l) Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- (m) In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- (n) Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- (o) Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and

(p) All such Eligible Equity Shareholders are deemed to have accepted the following:  
"I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation except under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.  
I/ We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transferred except in an offshore transaction in compliance with Regulation S, or otherwise pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.  
I/ We (i) am/ are, and the person, if any, for whose account I/ we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares is/ are, outside the U.S., (ii) am/ are not a "U.S. Person" as defined in ("Regulations"), and (iii) is/ are acquiring the Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.  
I/ We acknowledge that the Company, its affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where a Shareholder submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected. Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company, and the Registrar not having any liability to the Shareholders. The plain paper Application format will be available on the website of the Registrar at [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>. Our Company, and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date.

**LAST DATE FOR APPLICATION:** The last date for submission of the duly filled in the Application Form or a plain paper Application is 31<sup>st</sup> May 2024, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date). If the Application Form is not submitted with an SCSB, uploaded with the Stock Exchange and the Application Money is not blocked with the SCSB on or before the Issue Closing Date or such date as may be extended by our Board or any committee thereof, the invitation to offer contained in this Letter of offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as set out in "Basis of Allotment" mentioned on page 137 of the Letter of Offer.

**PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS:** The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market platform of the Stock Exchange (the "On Market Renunciation"); or (b) through an off-market transfer (the "Off Market Renunciation"), during the Renunciation Period. The Shareholders should have the demat Rights Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation and Off Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism. Shareholders may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock-broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholders on or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

**Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.**

**On Market Renunciation**  
The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchange through a registered stock-broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INE820Y20021 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will trade. The details for trading in Rights Entitlements will be as specified by the Stock Exchanges from time to time.

The Rights Entitlements are tradable in dematerialized form only. The market lot for trading of Rights Entitlements is one Rights Entitlement.

The On Market Renunciation shall take place only during the Renunciation Period for On Market Renunciation, i.e., from Tuesday, 21<sup>st</sup> May, 2024 to Monday, 27<sup>th</sup> May, 2024 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock-brokers by quoting the ISIN INE820Y20021 and indicating the details of the Rights Entitlements they intend to trade.

The Shareholders can place order for sale of Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The On Market Renunciation shall take place electronically on secondary market platform of NSE under automatic order matching mechanism and on T+2 rolling settlement basis; where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stock-broker will issue a contract note in accordance with the requirements of the Stock Exchange and the SEBI.

**Off Market Renunciation**  
The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off-market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only.

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat accounts of the Renouncees on or prior to the Issue Closing Date to enable Renouncees to subscribe to the Equity Shares in the Issue.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the ISIN INE820Y20021, the details of the buyer and the details of the Rights Entitlements they intend to transfer. The buyer of the Rights Entitlements (unless already having given a standing receipt instruction) has to issue a receipt instruction slip to their depository participant. The Shareholders can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants.

The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

**INVESTORS TO KINDLY NOTE THAT AFTER PURCHASING THE RIGHTS ENTITLEMENTS (RE) THROUGH ON MARKET RENUNCIATION / OFF MARKET RENUNCIATION, AN APPLICATION HAS TO BE MADE FOR SUBSCRIBING THE SHARES OFFERED UNDER RIGHTS ISSUE. IF NO APPLICATION IS MADE BY THE PURCHASER OF RES ON OR BEFORE ISSUE CLOSING DATE, THEN SUCH RES WILL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO SHARES FOR SUCH LAPSED RE WILL BE CREDITED, EVEN IF SUCH RE WERE PURCHASED FROM MARKET AND PURCHASER WILL LOSE THE AMOUNT PAID TO ACQUIRE THE RE. PERSONS WHO HAVE BOUGHT RIGHTS ENTITLEMENTS, SHALL REQUIRE TO MAKE AN APPLICATION AND APPLY FOR SHARES OFFERED UNDER RIGHTS ISSUE, IF THEY WANT TO SUBSCRIBE TO THE SHARES OFFERED UNDER RIGHTS ISSUE.**

**Fractional Entitlements**  
The Equity Shares are being offered on a rights basis to existing Eligible Equity Shareholders in the ratio of 1 (One) Equity Share for every 1 (One) Equity Share held as on the Record Date. As per SEBI Rights Issue Circulars, the fractional entitlements are to be ignored. In terms of present ratio, there will be no fractional shares.

**FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE RIGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION / OFF MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 118 OF THE LETTER OF OFFER.**

**LISTING AND TRADING OF THE RIGHTS EQUITY SHARES TO BE ISSUED PURSUANT TO THE ISSUE:** The existing Equity Shares are listed and traded on NSE (Script Code: AJOONI) under the ISIN: INE820Y01021. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of the final listing/trading approvals from the Stock Exchange. Upon receipt of such listing and trading approvals, the Equity Shares shall be debited from such temporary ISIN and credited to the new ISIN for the Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

**DISCLAIMER CLAUSE OF SEBI:** The Draft Letter of Offer has not been filed with SEBI in terms of SEBI ICDR Regulations as the size is below Rs. 5,000.00 lakhs. The present Issue being of less than Rs. 5,000 lakhs, our Company is in compliance with first proviso to Regulation 3 of the SEBI ICDR Regulations and our Company shall file the copy of the Letter of Offer prepared in accordance with the SEBI ICDR Regulations with SEBI for information and dissemination on the website of SEBI i.e. [www.sebi.gov.in](http://www.sebi.gov.in).

**DISCLAIMER CLAUSE OF NSE:** It is to be distinctly understood that the aforesaid permission given by NSE should not in any way be deemed or construed that the Letter of offer has been cleared or approved by NSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of the Letter of offer; nor does it warrant that this Issuer's securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer. The investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" beginning on page 110 of the LOF.

**DISPATCH AND AVAILABILITY OF ISSUE MATERIALS:** In accordance with the SEBI ICDR Regulations, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/ dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Further, this Letter of Offer will be sent/ dispatched to the Eligible Equity Shareholders who have provided Indian address and who have made a request in this regard. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Shareholders can access this Letter of Offer, the Abridged Letter of Offer and the Application Forms (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of:

- (i) Our Company at [www.ajoonibiotech.com](http://www.ajoonibiotech.com).
  - (ii) The Registrar at [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>
  - (iii) The Stock Exchange at [www.nseindia.com](http://www.nseindia.com)
- Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., **Cameo Corporate Services Ltd.** at [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>) by entering their DP ID and Client ID or Folio Number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company (i.e. [www.ajoonibiotech.com](http://www.ajoonibiotech.com)).

**BANKERS TO THE ISSUE: AXIS BANK LIMITED**

**MONITORING AGENCY:** Not Applicable

**FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF OTHER IMPORTANT LINKS AND HEADLINE:** The Investors can visit following links for the below-mentioned purposes:

- a) Frequently asked questions and online/ electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>
- b) Update of Indian address/ e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>
- c) Update of demat account details by Eligible Equity Shareholders holding shares in physical form: [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>
- d) Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders: [rights@cameoindia.com](https://rights.cameoindia.com).

**REGISTRAR TO THE ISSUE**

**CAMEO CORPORATE SERVICES LTD.**  
Subramanian Building, 1 Club House Road, Chennai 600 002.  
**Tel No.:** +044-40020700 (5 lines)  
**E-mail ID:** [rights@cameoindia.com](mailto:rights@cameoindia.com)  
**Investor Grievance Email:** [investor@cameoindia.com](mailto:investor@cameoindia.com)  
**Website:** [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>  
**Contact Person:** Ms. K. Sreerajya  
**SEBI Registration No:** INR000003753

**COMPANY SECRETARY AND COMPLIANCE OFFICER**

**Mrs. Swati Vujan**  
D-118, Industrial Area, Phase-7, Mohali Punjab - 160055  
**Tel: + 0172-5020762, Email:** [cs@ajoonibiotech.com](mailto:cs@ajoonibiotech.com), **Website:** [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

Investors may contact the Registrar to the Issue or the Company Secretary and Compliance Officer for any pre-issue/post-issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the applicant, number of Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the CAF, or the plain paper application, as the case may be, was submitted by the ASBA Investors.

#### CORRIGENDUM TO THE LETTER OF OFFER DATED 07<sup>TH</sup> MAY, 2024

The Eligible Equity Shareholders are requested to note that the Right issue has been approved by the Board of Directors of the Company in its meeting held on 14<sup>th</sup> October, 2023 and subsequent Board meeting held on 27<sup>th</sup> April, 2024.

- Accordingly, on page 39 of the Letter of Offer in Section IV - INTRODUCTION THE ISSUE under head "Authority for the Issue" shall be read as: The Equity Shares in the present issue are being offered pursuant to a resolution passed by our Board at its meeting held on 14<sup>th</sup> October, 2023 and subsequent meeting held on 27<sup>th</sup> April, 2024 in accordance with the provisions of the Companies Act.
- On page 52 of the Letter of Offer in Section IV - CAPITAL STRUCTURE shall be read as: The Issue has been authorized by a resolution of our Board passed at its meeting held on 14<sup>th</sup> October, 2023, and subsequent meeting held on 27<sup>th</sup> April, 2024 pursuant to Section 62 of the Companies Act, 2013.
- On page 108 of the Letter of Offer in Section VII - OTHER REGULATORY AND STATUTORY DISCLOSURES under head "Authority for the Issue" shall be read as: The Issue has been authorized by a resolution of our Board passed at its meeting held on 14<sup>th</sup> October, 2023, and subsequent meeting held on 27<sup>th</sup> April, 2024 pursuant to Section 62(1)(a) and other applicable provisions of the Companies Act, 2013.
- On page 145 of the Letter of Offer in Section IX - OTHER INFORMATION MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION under head "(B) Documents for Inspection" shall be read as: Copy of the resolution of the Board of Directors under Section 62 of the Companies Act passed in its meeting dated 14<sup>th</sup> October, 2023 and subsequent meeting held on 27<sup>th</sup> April, 2024 authorizing the Issue.

**INVESTORS MAY PLEASE NOTE THE LETTER OF OFFER, ABRIDGED LETTER OF OFFER, COMMON APPLICATION FORM, LETTER OF OFFER DATED MAY 07, 2024 SHALL BE READ IN CONJUNCTION WITH THIS CORRIGENDUM.**

For Ajooni Biotech Limited  
On Behalf of the Board of Directors  
Sd/-  
Mrs. Swati Vujan  
Company Secretary and Compliance Officer

**Disclaimer:** Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer dated 7<sup>th</sup> May, 2024 with the Securities and Exchange Board of India and NSE. The Letter of Offer is available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), website of Stock Exchange where the Equity Shares are listed i.e. NSE at [www.nseindia.com](http://www.nseindia.com). Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 23 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of offer dated 7<sup>th</sup> May, 2024 the "Letter of Offer" or ("LOF") filed with the National Stock Exchange of India Limited ("NSE"), and the Securities and Exchange Board of India ("SEBI").



# AJOONI BIOTECH LIMITED

(CIN-L85190PB2010PLC040162)

Our Company was originally incorporated at Chandigarh "Ajooni Biotech Private Limited" on 17<sup>th</sup> February, 2010 under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Consequent upon the conversion of our Company to public limited company, the name of our Company was changed to "Ajooni Biotech Limited" and fresh certificate of incorporation dated 27<sup>th</sup> September, 2017 was issued by the Registrar of Companies, Chandigarh, Punjab. For further details in relation to the changes to the name of our Company, please refer to the section titled "General Information" beginning on page 47 of this Letter of offer.

Registered Office: D-118, Industrial Area, Phase-7, Mohali Punjab -160055, Tel: +0172-5020758-69, Email Id: info@ajoonibiotech.com, Website: www.ajoonibiotech.com

Contact Person: Mrs. Swati Vijan, Company Secretary & Compliance Officer

## PROMOTERS OF OUR COMPANY: MR. JASJOT SINGH AND M/S HEALTHY BIOSCIENCES LIMITED

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF AJOONI BIOTECH LIMITED ONLY NEITHER OUR COMPANY, OUR PROMOTERS NOR OUR DIRECTORS HAVE BEEN DECLARED AS A WILFUL DEFAULTER OR FRAUDULENT BORROWER BY THE RBI OR ANY OTHER GOVERNMENT AUTHORITY.

### THE ISSUE

ISSUE OF UPTO 8,76,13,721 EQUITY SHARES OF FACE VALUE OF RS. 2 EACH ("EQUITY SHARES") OF AJOONI BIOTECH LIMITED ("ABL" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 5.00 PER EQUITY SHARE (INCLUDING PREMIUM OF RS. 3.00 PER EQUITY SHARE) ("ISSUE PRICE") FOR AN AGGREGATE AMOUNT NOT EXCEEDING RS. 4,380.69 LACS TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. 7<sup>th</sup> MAY, 2024 (THE "ISSUE"). THE ISSUE PRICE IS 2.50 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 115 OF THIS LETTER OF OFFER.

### ISSUE PROGRAMME

ISSUE OPENS ON

LAST DATE OF MARKET RENUNCIATIONS\*

ISSUE CLOSES ON\*\*

TUESDAY, 21<sup>ST</sup> MAY, 2024

MONDAY, 27<sup>TH</sup> MAY, 2024

FRIDAY, 31<sup>ST</sup> MAY, 2024

\*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renounee(s) on or prior to the Issue Closing Date.

\*\*Our Board or a Rights Issue committee thereof will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

#### ASBA\*

Simple, Safe, Smart way of Application - Make use of it!!!

\*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below.

In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/ CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/CIR/CFD/DIL/67/2020 dated April 21, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/78 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/136 dated July 24, 2020 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2021/633 dated 01 October 2021 (Collectively hereafter referred to as "SEBI Rights Issue Circulars") and SEBI circular SEBI/CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL/1/2011 dated April 29, 2011 and the SEBI circular, bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022 (Collectively hereafter referred to as "ASBA Circulars"), all Shareholders desiring to make an Application in this issue are mandatorily required to use the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Making of an Application through the ASBA Process" on page 118 of the Letter of Offer.

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialised form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two Working Days prior to the Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shares in physical form, and whose demat account details are not available with our Company or the Registrar, shall be credited in a demat suspense escrow account opened by our Company.

Please note that if Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date, have not provided the details of their demat accounts to our Company or to the Registrar, they are required to provide their demat account details to our Company or the Registrar not later than two Working Days prior to the Issue Closing Date, i.e., 29<sup>th</sup> May, 2024 to enable the credit of the Rights Entitlements by way of transfer from the demat suspense escrow account to their respective demat accounts, at least one day before the Issue Closing Date, i.e., 30<sup>th</sup> May, 2024.

**PROCEDURE FOR APPLICATION:** In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars and the ASBA Circulars, all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details of procedure for application by the resident Eligible Equity Shareholders holding Equity Shares in physical form as on the Record Date, i.e., 7<sup>th</sup> May, 2024, see "Procedure for Application by Eligible Equity Shareholders holding Equity Shares in physical form" on page 121 of the Letter of Offer.

**PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS:** Shareholders, wishing to participate in this Issue through the ASBA facility, is required to have an ASBA enabled bank account with an SCSB, prior to making the Application. Shareholders desiring to make an Application in this Issue through ASBA process, may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for authorizing such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

#### Self-Certified Syndicate Banks:

For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFnl=yes&intmid=34>.

**APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARES IN PHYSICAL FORM:** Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialised form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two Working Days prior to the Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

**ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM:** PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE I.E., 07<sup>th</sup> MAY, 2024.

**DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM:** The Dispatch of the ALOF and Application Form for the Issue was completed on 14<sup>th</sup> May, 2024 by the Registrar to the Issue.

**CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS:** In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialized form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "AJOONI BIOTECH LIMITED SUSPENSE ESCROW DEMAT ACCOUNT") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or suspended for debit or credit or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI Listing Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two Working Days prior to the Issue Closing Date, i.e., by 29<sup>th</sup> May, 2024 to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in this Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar account is active to facilitate the aforementioned transfer.

**APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS:** The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being Ajooni Biotech Limited;
- Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);
- Folio Number (in case of Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date)/DP and Client ID;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to this Issue.
- Number of Equity Shares held as on Record Date;
- Allotment option – only dematerialised form;
- Number of Equity Shares entitled to;
- Number of Equity Shares applied for within the Rights Entitlements;
- Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Equity Shares applied for;
- Total amount paid at the rate of Rs. 5/- per Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and

(p) All such Eligible Equity Shareholders are deemed to have accepted the following:

"I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation except under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.

I/ We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transferred except in an offshore transaction in compliance with Regulation S, or otherwise pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.

I/ We (i) am/ are, and the person, if any, for whose account I/ we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares is/ are, outside the U.S., (ii) am/ are not a "U.S. Person" as defined in ("Regulations"), and (iii) is/ are acquiring the Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.

I/ We acknowledge that the Company, its affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where a Shareholders submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected.

Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company, and the Registrar not having any liability to the Shareholders. The plain paper Application format will be available on the website of the Registrar at [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>. Our Company, and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date.

**LAST DATE FOR APPLICATION:** The last date for submission of the duly filled in the Application Form or a plain paper Application is 31<sup>st</sup> May 2024, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date). If the Application Form is not submitted with an SCSB, uploaded with the Stock Exchange and the Application Money is not blocked with the SCSB on or before the Issue Closing Date or such date as may be extended by our Board or any committee thereof, the invitation to offer contained in this Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as set out in "Basis of Allotment" mentioned on page 137 of the Letter of Offer.

**PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS:** The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market platform of the Stock Exchange (the "On Market Renunciation"); or (b) through an off-market transfer (the "Off Market Renunciation"), during the Renunciation Period. The Shareholders should have the demat Rights Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation and Off Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Shareholders may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock-broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholders on or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.

#### On Market Renunciation

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchange through a registered stock-broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INE820Y20021 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will trade. The details for trading in Rights Entitlements will be as specified by the Stock Exchanges from time to time.

The Rights Entitlements are tradable in dematerialized form only. The market lot for trading of Rights Entitlements is one Rights Entitlement.

The On Market Renunciation shall take place only during the Renunciation Period for On Market Renunciation, i.e., from Tuesday, 21<sup>st</sup> May, 2024 to Monday, 27<sup>th</sup> May, 2024 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock-brokers by quoting the ISIN INE820Y20021 and indicating the details of the Rights Entitlements they intend to trade.

The Shareholders can place order for sale of Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The On Market Renunciation shall take place electronically on secondary market platform of NSE under automatic order matching mechanism and on "T+2 rolling settlement basis", where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stock-broker will issue a contract note in accordance with the requirements of the Stock Exchange and the SEBI.

#### Off Market Renunciation

The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off-market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only.

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat accounts of the Renounee(s) on or prior to the Issue Closing Date to enable Renounees to subscribe to the Equity Shares in the Issue.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the ISIN INE820Y20021, the details of the buyer and the details of the Rights Entitlements they intend to transfer. The buyer of the Rights Entitlements (unless already having given a standing receipt instruction) has to issue a receipt instruction slip to their depository participant. The Shareholders can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants.

The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

**INVESTORS TO KINDLY NOTE THAT AFTER PURCHASING THE RIGHTS ENTITLEMENTS (RE) THROUGH ON MARKET RENUNCIATION / OFF MARKET RENUNCIATION, AN APPLICATION HAS TO BE MADE FOR SUBSCRIBING THE SHARES OFFERED UNDER RIGHTS ISSUE. IF NO APPLICATION IS MADE BY THE PURCHASER OF RES ON OR BEFORE ISSUE CLOSING DATE, THEN SUCH RES WILL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO SHARES FOR SUCH LAPSED RE WILL BE CREDITED, EVEN IF SUCH RE WERE PURCHASED FROM MARKET AND PURCHASER WILL LOSE THE AMOUNT PAID TO ACQUIRE THE RE. PERSONS WHO HAVE BOUGHT RIGHTS ENTITLEMENTS, SHALL REQUIRE TO MAKE AN APPLICATION AND APPLY FOR SHARES OFFERED UNDER RIGHTS ISSUE, IF THEY WANT TO SUBSCRIBE TO THE SHARES OFFERED UNDER RIGHTS ISSUE.**

#### Fractional Entitlements

The Equity Shares are being offered on a rights basis to existing Eligible Equity Shareholders in the ratio of 1 (One) Equity Share for every 1 (One) Equity Share held as on the Record Date. As per SEBI Rights Issue Circulars, the fractional entitlements are to be ignored. In terms of present ratio, there will no fractional shares.

**FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE RIGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION / OFF MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 118 OF THE LETTER OF OFFER.**

**LISTING AND TRADING OF THE RIGHTS EQUITY SHARES TO BE ISSUED PURSUANT TO THE ISSUE:** The existing Equity Shares are listed and traded on NSE (Script Code: AJOONI) under the ISIN: INE820Y01021. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of the final listing/trading approvals from the Stock Exchange. Upon receipt of such listing and trading approvals, the Equity Shares shall be debited from such temporary ISIN and credited to the new ISIN for the Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

**DISCLAIMER CLAUSE OF SEBI:** The Draft Letter of Offer has not been filed with SEBI in terms of SEBI ICDR Regulations as the size is below Rs. 5,000.00 lakhs. The present Issue being of less than Rs. 5,000 lakhs, our Company is in compliance with first proviso to Regulation 3 of the SEBI ICDR Regulations and our Company shall file the copy of the Letter of Offer prepared in accordance with the SEBI ICDR Regulations with SEBI for information and dissemination on the website of SEBI i.e. [www.sebi.gov.in](http://www.sebi.gov.in).

**DISCLAIMER CLAUSE OF NSE:** It is to be distinctly understood that the aforesaid permission given by NSE should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by NSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of the Letter of Offer; nor does it warrant that this Issuer's securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer. The Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" beginning on page 110 of the LOF.

**DISPATCH AND AVAILABILITY OF ISSUE MATERIALS:** In accordance with the SEBI ICDR Regulations, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/ dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Further, this Letter of Offer will be sent/ dispatched to the Eligible Equity Shareholders who have provided Indian address, and who have made a request in this regard. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Shareholders can access this Letter of Offer, the Abridged Letter of Offer and the Application Forms (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of:

- Our Company at [www.ajoonibiotech.com](http://www.ajoonibiotech.com)
- The Registrar at [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>
- The Stock Exchange at [www.nseindia.com](http://www.nseindia.com)

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., Cameo Corporate Services Ltd. at [www.cameoindia.com](http://www.cameoindia.com) / <https://rights.cameoindia.com/ajooni1>) by entering their DP ID and Client ID or Folio Number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company (i.e. [www.ajoonibiotech.com](http://www.ajoonibiotech.com)).

#### BANKERS TO THE ISSUE: AXIS BANK LIMITED

MONITORING AGENCY: Not Applicable

**FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF OTHER IMPORTANT LINKS AND HELPLINE:** The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/electronic designated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: [www.cameoindia.com/\\_https://rights.cameoindia.com/ajooni1](http://www.cameoindia.com/_https://rights.cameoindia.com/ajooni1)
- Update of Indian address/ e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: [www.cameoindia.com/\\_https://rights.cameoindia.com/ajooni1](http://www.cameoindia.com/_https://rights.cameoindia.com/ajooni1)
- Update of demat account details by Eligible Equity Shareholders holding shares in physical form: [www.cameoindia.com/\\_https://rights.cameoindia.com/ajooni1](http://www.cameoindia.com/_https://rights.cameoindia.com/ajooni1)
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders: [rights@cameoindia.com](mailto:rights@cameoindia.com)

REGISTRAR TO THE ISSUE	
	<b>CAMEO CORPORATE SERVICES LTD.</b> Subramanian Building, 1 Club House Road, Chennai 600 002. Tel No.: +044-40020700 (5 lines) E-mail ID: <a href="mailto:rights@cameoindia.com">rights@cameoindia.com</a> Investor Grievance Email: <a href="mailto:investor@cameoindia.com">investor@cameoindia.com</a> Website: <a href="http://www.cameoindia.com">www.cameoindia.com</a> / <a href="https://rights.cameoindia.com/ajooni1">https://rights.cameoindia.com/ajooni1</a> Contact Person: Ms. K. Sreepriya SEBI Registration No: INR000003753

COMPANY SECRETARY AND COMPLIANCE OFFICER	
	<b>Mrs. Swati Vijan</b> D-118, Industrial Area, Phase-7, Mohali Punjab - 160055 Tel: + 0172-5020762, Email: <a href="mailto:cs@ajoonibiotech.com">cs@ajoonibiotech.com</a> , Website: <a href="http://www.ajoonibiotech.com">www.ajoonibiotech.com</a>

Investors may contact the Registrar to the Issue or the Company Secretary and Compliance Officer for any pre-Issue/post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the applicant, number of Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the CAF, or the plain paper application, as the case may be, was submitted by the ASBA Investors.

#### CORRIGENDUM TO THE LETTER OF OFFER DATED 07<sup>th</sup> MAY, 2024

The Eligible Equity Shareholders are requested to note that the Right Issue has been approved by the Board of Directors of the Company in its meeting held on 14<sup>th</sup> October, 2023 and subsequent Board meeting held on 27<sup>th</sup> April, 2024.

- Accordingly, on page 39 of the Letter of Offer in Section IV - INTRODUCTION THE ISSUE under head "Authority for the Issue" shall be read as: The Equity Shares in the present issue are being offered pursuant a resolution passed by our Board at its meeting held on 14<sup>th</sup> October, 2023 and subsequent meeting held on 27<sup>th</sup> April, 2024 in accordance with the provisions of the Companies Act.
- On page 52 of the Letter of Offer in Section IV - CAPITAL STRUCTURE shall be read as: The Issue has been authorized by a resolution of our Board passed at its meeting held on 14<sup>th</sup> October, 2023, and subsequent meeting held on 27<sup>th</sup> April, 2024 pursuant to Section 62 of the Companies Act, 2013.
- On page 108 of the Letter of Offer in Section VII - OTHER REGULATORY AND STATUTORY DISCLOSURES under head "Authority for the Issue" shall be read as: The Issue has been authorized by a resolution of our Board passed at its meeting held on 14<sup>th</sup> October, 2023, and subsequent meeting held on 27<sup>th</sup> April, 2024 pursuant to Section 62(1)(a) and other applicable provisions of the Companies Act, 2013.
- On page 145 of the Letter of Offer in Section IX - OTHER INFORMATION MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION under head "(B) Documents for Inspection" shall be read as: Copy of the resolution of the Board of Directors under Section 62 of the Companies Act passed in its meeting dated 14<sup>th</sup> October, 2023 and subsequent meeting held on 27<sup>th</sup> April, 2024 authorizing the Issue.

**INVESTORS MAY PLEASE NOTE THE LETTER OF OFFER, ABRIDGED LETTER OF OFFER, COMMON APPLICATION FORM, LETTER OF OFFER DATED 07, 2024 SHALL BE READ IN CONJUNCTION WITH THIS CORRIGENDUM.**

For Ajooni Biotech Limited  
On Behalf of the Board of Directors  
Sd/-  
Mrs. Swati Vijan  
Company Secretary and Compliance Officer

Date: 16<sup>th</sup> May, 2024  
Place: Mohali, Punjab

**Disclaimer:** Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer dated 7<sup>th</sup> May, 2024 with the Securities and Exchange Board of India and NSE. The Letter of Offer is available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), website of Stock Exchange where the Equity Shares are listed i.e. NSE at [www.nseindia.com](http://www.nseindia.com). Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 23 of the Letter of Offer. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.

ਸ਼ੁਰਿੰਦਰ ਸਿੰਘ ਚੌਠਾ  
ਗਿੱਦੜਬਾਗ, 16 ਮਈ : ਸਿਵਲ ਸਰਜਨ  
ਡਾਕਟਰ ਨਵਜੌਤ ਕੌਰ ਅਤੇ ਐਪੀਡਮਿਓਲੋਜਿਸਟ  
ਡਾਕਟਰ ਸੰਦੀਪ ਕੌਰ ਦੇ ਦਿਸ਼ਾ ਨਿਰਦੇਸ਼ਾਂ  
ਅਨੁਸਾਰ ਡਾਕਟਰ ਰਸਮੀ ਚਾਵਲਾ ਜੀ ਦੀ  
ਯੋਗ ਅਗਵਾਈ ਹੇਠ ਰਾਸ਼ਟਰੀ ਡੇਂਗੂ ਦਿਵਸ

ਮਨਾਇਆ ਗਿਆ। ਇਸ ਮੌਕੇ ਡਾਕਟਰ ਰਸਮੀ  
ਚਾਵਲਾ ਨੇ ਦੱਸਿਆ ਕਿ ਡੇਂਗੂ ਦਾ ਮੱਛਰ ਸਾਫ  
ਖੜੇ ਪਾਣੀ ਦੇ ਸੰਪਰਿਕ ਵਿੱਚ ਪੈਂਦਾ ਹੁੰਦਾ  
ਹੈ ਅਤੇ ਸਿਰਫ ਦਿਨ ਵੇਲੇ ਕੱਟਦਾ ਹੈ। ਇਸ  
ਦੇ ਲੱਛਣ ਤੇਜ਼ ਖੁਬਾਰ ਹੋਣਾ, ਸਿਰ ਦਰਦ,  
ਮਾਸਪੇਸ਼ੀਆਂ ਦਾ ਦਰਦ, ਚਮੜੀ ਉੱਤੇ ਦਾਣੇ,

# ਸਿਵਲ ਹਸਪਤਾਲ ਗਿੱਦੜਬਾਗ ਵਿਖੇ ਕੌਮੀ ਡੇਂਗੂ ਦਿਵਸ ਮਨਾਇਆ

ਅੱਖਾਂ ਦੇ ਪਿਛਲੇ ਹਿੱਸੇ ਵਿੱਚ ਦਰਦ, ਮਸੂੜਿਆਂ  
ਅਤੇ ਨੱਕ ਵਿੱਚੋਂ ਖੂਨ ਦਾ ਵਗਣਾ ਆਦਿ ਹੈ  
ਇਸ ਮੌਕੇ ਤੇ ਐਸਐਮਓ ਰਸਮੀ ਚਾਵਲਾ ਨੇ  
ਡੇਂਗੂ ਦੇ ਬਚਾਵ ਸਬੰਧੀ ਦੱਸਿਆ ਕਿ ਕੁਲਰਾਂ ਤੇ

ਗਮਲੇ ਅਤੇ ਫਰਿਜਾਂ ਦੀਆਂ ਟਰੇਆਂ ਵਿੱਚ ਖੜੇ  
ਪਾਣੀ ਨੂੰ ਹਰ ਦਿਨ ਵਿੱਚ ਇੱਕ ਵਾਰ ਜ਼ਰੂਰ ਸਾਫ  
ਕਰੋ, ਅਜਿਹੇ ਕੱਪੜੇ ਪਹਿਨੇ ਜਿਸ ਨਾਲ ਸਰੀਰ  
ਢਕਿਆ ਰਹੇ ਤਾਂ ਕਿ ਤੁਹਾਨੂੰ ਮੱਛਰ ਨਾ ਕੱਟ

ਸਕੇ, ਸੋਣ ਵੇਲੇ ਮੱਛਰਦਾਨੀ ਮੱਛਰ ਭਜਾਉਣ  
ਵਾਲੀਆਂ ਕਰੀਮਾਂ ਅਤੇ ਤੇਲ ਆਦਿ ਦਾ  
ਇਸਤੇਮਾਲ ਕਰੋ, ਖੁਬਾਰ ਹੋਣ ਤੇ ਐਸਪੀਰੇਨ  
ਅਤੇ ਬੁਰਫ ਨਾ ਲਵੋ, ਖੁਬਾਰ ਹੋਣ ਤੇ ਸਿਰਫ

ਪੈਰਾਸਿਟੋਲ ਨਹੀਂ ਲਵੋ, ਛੱਤਾਂ ਤੇ ਰੌਸ਼ੀਆਂ  
ਪਾਣੀ ਦੀਆਂ ਟੈਂਕੀਆਂ ਦੇ ਢੱਕਣਾਂ ਨੂੰ ਚੰਗੀ  
ਤਰ੍ਹਾਂ ਥੋਕ ਰੱਖੋ, ਟੁੱਟੇ ਬਰਤਨਾਂ ਅਤੇ ਟਾਇਰਾਂ  
ਆਦਿ ਨੂੰ ਖੁੱਲ੍ਹੇ ਵਿੱਚ ਨਾ ਰੱਖੋ, ਪਾਣੀ ਜਾਂ ਤਰਲ

ਪਾਣੀ ਦਾ ਇਸਤੇਮਾਲ ਜਿਜ਼ਾਦਾ ਕਰੋ ਅਤੇ  
ਆਰਾਮ ਕਰੋ ਸ਼ਹਿਰ ਵਾਸੀਆਂ ਨੂੰ ਅਪੀਲ ਕੀਤੀ  
ਜਾਂਦੀ ਹੈ ਕਿ ਡੇਂਗੂ ਦਾ ਮੱਛਰ ਹਰ ਦਿਨ ਵਿੱਚ ਆਂਡੇ  
ਤੋਂ ਪੂਰਾ ਮੱਛਰ ਤਿਆਰ ਹੋ ਜਾਂਦਾ ਹੈ। ਇਸ  
ਲਈ ਕੁਲਰਾਂ ਗਮਲਿਆਂ ਅਤੇ ਫਰਿਜਾਂ ਦੀਆਂ  
ਟਰੇਆਂ ਅਤੇ ਹੋਰ ਪਾਣੀ ਦੇ ਭਾਂਡਿਆਂ ਨੂੰ ਹਰ  
ਹਫਤੇ ਚੰਗੀ ਤਰ੍ਹਾਂ ਸਾਫ ਕਰੋ ਅਤੇ ਸ਼ੱਕਾ ਰੱਖਿਆ

ਜਾਂਦੇ। ਪਾਣੀ ਦੇ ਟੈਂਕੀਆਂ ਨੂੰ ਸਿੱਟੀ ਨਾਲ ਭਰ  
ਦਿਓ। ਡੇਂਗੂ ਦਾ ਟੈਸਟ ਅਤੇ ਇਲਾਜ ਸਰਕਾਰੀ  
ਹਸਪਤਾਲ ਵਿੱਚ ਮੁਫਤ ਕੀਤਾ ਜਾਂਦਾ ਹੈ। ਇਸ  
ਮੌਕੇ ਸੁਖਜਿੰਦਰ ਕੌਰ, ਜਸਵਿੰਦਰਪਾਲ ਜੱਸੀ,  
ਪ੍ਰਿੰਸ ਕੁਮਾਰ, ਮੰਗਲ ਸਿੰਘ, ਨੈਨਸੀ ਮੋਗਾ,  
ਨਰੇਸ਼ ਕੁਮਾਰ, ਨਰਸਿੰਗ ਸਟੂਡੈਂਟ ਅਤੇ ਹੋਰ  
ਸਟਾਫ ਹਾਜ਼ਰ ਸਨ।

This advertisement is for information purposes only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell securities. This is not an announcement for the offer document. All capitalized terms used herein and not defined herein shall have the meaning assigned to them in the Letter of offer dated 7<sup>th</sup> May, 2024 the "Letter of Offer" or ("LOF") filed with the National Stock Exchange of India Limited ("NSE"), and the Securities and Exchange Board of India ("SEBI").

# AJOONI BIOTECH LIMITED

(CIN-L85190PB2010PLC040162)

Our Company was originally incorporated at Chandigarh "Ajooni Biotech Private Limited" on 17<sup>th</sup> February, 2010 under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. Consequent upon the conversion of our Company to public limited company, the name of our Company was changed to "Ajooni Biotech Limited" and fresh certificate of incorporation dated 27<sup>th</sup> September, 2017 was issued by the Registrar of Companies, Chandigarh, Punjab. For further details in relation to the changes to the name of our Company, please refer to the section titled "General Information" beginning on page 47 of this Letter of offer.

## PROMOTERS OF OUR COMPANY: MR. JASJOT SINGH AND M/S HEALTHY BIOSCIENCES LIMITED

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF AJOONI BIOTECH LIMITED ONLY NEITHER OUR COMPANY, OUR PROMOTERS NOR OUR DIRECTORS HAVE BEEN DECLARED AS A WILFUL DEFAULTER OR FRAUDULENT BORROWER BY THE RBI OR ANY OTHER GOVERNMENT AUTHORITY.

### THE ISSUE

ISSUE OF UPTO 8,76,13,721 EQUITY SHARES OF FACE VALUE OF RS. 2 EACH ("EQUITY SHARES") OF AJOONI BIOTECH LIMITED ("ABI" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF RS. 5.00 PER EQUITY SHARE (INCLUDING PREMIUM OF RS. 3.00 PER EQUITY SHARE) ("ISSUE PRICE") FOR AN AGGREGATE AMOUNT NOT EXCEEDING RS. 4,380.69 LACS TO THE ELIGIBLE EQUITY SHAREHOLDERS ON RIGHTS BASIS IN THE RATIO OF 1 (ONE) EQUITY SHARE FOR EVERY 1 (ONE) EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, I.E. 7<sup>th</sup> MAY, 2024 (THE "ISSUE"). THE ISSUE PRICE IS 2.50 TIMES OF FACE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE SEE THE CHAPTER TITLED "TERMS OF THE ISSUE" ON PAGE 115 OF THIS LETTER OF OFFER.

### ISSUE PROGRAMME

ISSUE OPENS ON	LAST DATE OF MARKET RENUNCIATIONS*	ISSUE CLOSES ON**
TUESDAY, 21 <sup>ST</sup> MAY, 2024	MONDAY, 27 <sup>TH</sup> MAY, 2024	FRIDAY, 31 <sup>ST</sup> MAY, 2024

\*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncee(s) on or prior to the Issue Closing Date.  
\*\*Our Board or a Rights Issue committee thereof will have the right to extend the Issue period as it may determine from time to time but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

<b>ASBA*</b>	<b>Simple, Safe, Smart way of Application - Make use of it!!!</b>	<b>*Applications Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check section on ASBA below.</b>
--------------	-------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In accordance with Regulation 76 of the SEBI ICDR Regulations, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/ CIR/P/2020/13 dated January 22, 2020, SEBI circular bearing reference number SEBI/HO/CFD/CIR/CFD/DIL/67/2020 dated April 21, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/78 dated May 6, 2020, SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/136 dated July 24, 2020 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2021/633 dated 01 October 2021 (Collectively hereafter referred to as "SEBI Rights Issue Circulars") and SEBI circular SEBI/CFD/DIL/ASBA/1/2009/30/12 dated December 30, 2009, SEBI circular CIR/CFD/DIL/1/2011 dated April 29, 2011 and the SEBI circular, bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020 and SEBI circular bearing reference number SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022 (Collectively hereafter referred to as "ASBA Circulars"), all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details, see "Making of an Application through the ASBA Process" on page 118 of the Letter of Offer.

Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialised form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two Working Days prior to the Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

Prior to the Issue Opening Date, the Rights Entitlements of those Eligible Equity Shareholders, among others, who hold Equity Shares in physical form, and whose demat account details are not available with our Company or the Registrar, shall be credited in a demat suspense escrow account opened by our Company.  
Please note that if Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date, have not provided the details of their demat accounts to our Company or to the Registrar, they are required to provide their demat account details to our Company or the Registrar not later than two Working Days prior to the Issue Closing Date, i.e., 29<sup>th</sup> May, 2024 to enable the credit of the Rights Entitlements by way of transfer from the demat suspense escrow account to their respective demat accounts, at least one day before the Issue Closing Date, i.e., 30<sup>th</sup> May, 2024.

**PROCEDURE FOR APPLICATION:** In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Rights Issue Circulars and the ASBA Circulars, all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA. For details of procedure for application by the resident Eligible Equity Shareholders holding Equity Shares in physical form as on the Record Date i.e., 7<sup>th</sup> May, 2024, see "Procedure for Application by Eligible Equity Shareholders holding Equity Shares in physical form" on page 121 of the Letter of Offer.

**PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS:** Shareholders, wishing to participate in this Issue through the ASBA facility, is required to have an ASBA enabled bank account with a SCSB, prior to making the Application. Shareholders desiring to make an Application in this Issue through ASBA process, may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/ electronic Application through the website of the SCSBs (if made available by such SCSB) for authorizing such SCSB to block Application Money payable on the Application in their respective ASBA Accounts.

Shareholders should ensure that they have correctly submitted the Application Form and have provided an authorisation to the SCSB, via the electronic mode, for blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application.

**Self-Certified Syndicate Banks:**  
For the list of banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?do=Recognition&fpi=yes&intmid=34>.

**APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS HOLDING EQUITY SHARES IN PHYSICAL FORM:** Please note that in accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialised form only. Accordingly, Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date and desirous of subscribing to Equity Shares in this Issue are advised to furnish the details of their demat account to the Registrar or our Company at least two Working Days prior to the Issue Closing Date, to enable the credit of their Rights Entitlements in their respective demat accounts at least one day before the Issue Closing Date.

**ALLOTMENT OF THE RIGHTS EQUITY SHARES IN DEMATERIALIZED FORM:** PLEASE NOTE THAT THE RIGHTS EQUITY SHARES APPLIED FOR IN THIS ISSUE CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH OUR EQUITY SHARES ARE HELD BY SUCH INVESTOR ON THE RECORD DATE i.e., 07<sup>th</sup> MAY, 2024.

**DISPATCH OF THE ABRIDGED LETTER OF OFFER ("ALOF") AND APPLICATION FORM:** The Dispatch of the ALOF and Application Form for the Issue was completed on 14<sup>th</sup> May, 2024 by the Registrar to the Issue.

**CREDIT OF RIGHTS ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS:** In accordance with Regulation 77A of the SEBI ICDR Regulations read with the SEBI Rights Issue Circulars, the credit of Rights Entitlements and Allotment of Equity Shares shall be made in dematerialised form only. Prior to the Issue Opening Date, our Company shall credit the Rights Entitlements to (i) the demat accounts of the Eligible Equity Shareholders holding the Equity Shares in dematerialised form; and (ii) a demat suspense escrow account (namely, "AJOONI BIOTECH LIMITED SUSPENSE ESCROW DEMAT ACCOUNT") opened by our Company, for the Eligible Equity Shareholders which would comprise Rights Entitlements relating to (a) Equity Shares held in the account of the IEPF authority; or (b) the demat accounts of the Eligible Equity Shareholder which are frozen or suspended for debit or credit or the Equity Shares which are lying in the unclaimed suspense account (including those pursuant to Regulation 39 of the SEBI Listing Regulations) or details of which are unavailable with our Company or with the Registrar on the Record Date; or (c) Equity Shares held by Eligible Equity Shareholders holding Equity Shares in physical form as on Record Date where details of demat accounts are not provided by Eligible Equity Shareholders to our Company or Registrar; or (d) credit of the Rights Entitlements returned/reversed/failed; or (e) the ownership of the Equity Shares currently under dispute, including any court proceedings, if any; or (f) non-institutional equity shareholders in the United States.

Eligible Equity Shareholders are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of demat account etc., details/records confirming the legal and beneficial ownership of their respective Equity Shares) to our Company or the Registrar not later than two Working Days prior to the Issue Closing Date, i.e., by 29<sup>th</sup> May, 2024 to enable the credit of their Rights Entitlements by way of transfer from the demat suspense escrow account to their demat account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in this Issue, and this communication shall serve as an intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar account is active to facilitate the aforementioned transfer.

**APPLICATIONS ON PLAIN PAPER UNDER ASBA PROCESS:** The Application on plain paper, duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per specimen recorded with his/her bank, must reach the office of the Designated Branch of the SCSB before the Issue Closing Date and should contain the following particulars:

- Name of our Company, being Ajooni Biotech Limited;
- Name and address of the Eligible Equity Shareholder including joint holders (in the same order and as per specimen recorded with our Company or the Depository);
- Folio Number (in case of Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date)/DP and Client ID;
- Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the officials appointed by the courts, PAN of the Eligible Equity Shareholder and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to this Issue
- Number of Equity Shares held as on Record Date;
- Allotment option – only dematerialised form;
- Number of Equity Shares entitled to;
- Number of Equity Shares applied for within the Rights Entitlements;
- Number of additional Equity Shares applied for, if any (applicable only if entire Rights Entitlements have been applied for);
- Total number of Equity Shares applied for;
- Total amount paid at the rate of Rs. 5/- per Equity Share;
- Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB;
- In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FNRR/NRO account such as the account number, name, address and branch of the SCSB with which the account is maintained;
- Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account;
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and

(p) All such Eligible Equity Shareholders are deemed to have accepted the following:  
"I/ We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation except under circumstances that will result in compliance with any applicable laws or regulations. We satisfy, and each account for which we are acting satisfies, all suitability standards for Shareholders in investments of the type subscribed for herein imposed by the jurisdiction of our residence.  
I/ We understand and agree that the Rights Entitlement and Rights Equity Shares may not be reoffered, resold, pledged or otherwise transferred except in an offshore transaction in compliance with Regulation S, or otherwise pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act.  
I/ We (i) am/ are, and the person, if any, for whose account I/ we am/ are acquiring such Rights Entitlement and/ or the Rights Equity Shares is/ are, outside the U.S., (ii) am/ are not a "U.S. Person" as defined in ("Regulations"), and (iii) is/ are acquiring the Rights Entitlement and/ or the Rights Equity Shares in an offshore transaction meeting the requirements of Regulations.  
I/ We acknowledge that the Company, its affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements credited to the same demat account or in demat suspense escrow account, as applicable, including cases where a Shareholders submits Application Forms along with a plain paper Application, such Applications shall be liable to be rejected. Shareholders are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company, and the Registrar not having any liability to the Shareholders. The plain paper Application format will be available on the website of the Registrar at [www.cameoindia.com/https://rights.cameoindia.com/ajooni1](http://www.cameoindia.com/https://rights.cameoindia.com/ajooni1) Our Company, and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the Shareholders' ASBA Accounts on or before the Issue Closing Date.

**LAST DATE FOR APPLICATION:** The last date for submission of the duly filled in the Application Form or a plain paper Application is 31<sup>st</sup> May 2024, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as it may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date). If the Application Form is not submitted with an SCSB, uploaded with the Stock Exchange and the Application Money is not blocked with the SCSB on or before the Issue Closing Date or such date as may be extended by our Board or any committee thereof, the invitation to offer contained in this Letter of offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as set out in "Basis of Allotment" mentioned on page 137 of the Letter of Offer.

**PROCEDURE FOR RENUNCIATION OF RIGHTS ENTITLEMENTS:** The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts, either in full or in part (a) by using the secondary market platform of the Stock Exchange (the "On Market Renunciation"); or (b) through an off-market transfer (the "Off Market Renunciation") during the Renunciation Period. The Shareholders should have the demat Rights Entitlements credited/lying in his/her own demat account prior to the renunciation. The trades through On Market Renunciation and Off Market Renunciation will be settled by transferring the Rights Entitlements through the depository mechanism.

Shareholders may be subject to adverse foreign, state or local tax or legal consequences as a result of trading in the Rights Entitlements. Shareholders who intend to trade in the Rights Entitlements should consult their tax advisor or stock-broker regarding any cost, applicable taxes, charges and expenses (including brokerage) that may be levied for trading in Rights Entitlements.

Please note that the Rights Entitlements which are neither renounced nor subscribed by the Shareholders on or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

**Our Company accept no responsibility to bear or pay any cost, applicable taxes, charges and expenses (including brokerage), and such costs will be incurred solely by the Shareholders.**

**On Market Renunciation**  
The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by trading/selling them on the secondary market platform of the Stock Exchange through a registered stock-broker in the same manner as the existing Equity Shares of our Company.

In this regard, in terms of provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars, the Rights Entitlements credited to the respective demat accounts of the Eligible Equity Shareholders shall be admitted for trading on the Stock Exchanges under ISIN INE820Y20021 subject to requisite approvals. Prior to the Issue Opening Date, our Company will obtain the approval from the Stock Exchanges for trading of Rights Entitlements. No assurance can be given regarding the active or sustained On Market Renunciation or the price at which the Rights Entitlements will trade. The details for trading in Rights Entitlements will be as specified by the Stock Exchanges from time to time.

The Rights Entitlements are tradable in dematerialized form only. The market lot for trading of Rights Entitlements is one Rights Entitlement.

The On Market Renunciation shall take place only during the Renunciation Period for On Market Renunciation, i.e., from Tuesday, 21<sup>st</sup> May, 2024 to Monday, 27<sup>th</sup> May, 2024 (both days inclusive).

The Shareholders holding the Rights Entitlements who desire to sell their Rights Entitlements will have to do so through their registered stock-brokers by quoting the ISIN INE820Y20021 and indicating the details of the Rights Entitlements they intend to trade.

The Shareholders can place order for sale of Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The On Market Renunciation shall take place electronically on secondary market platform of NSE under automatic order matching mechanism and on T+2 rolling settlement basis, where 'T' refers to the date of trading. The transactions will be settled on trade-for-trade basis. Upon execution of the order, the stock-broker will issue a contract note in accordance with the requirements of the Stock Exchange and the SEBI.

**Off Market Renunciation**  
The Eligible Equity Shareholders may renounce the Rights Entitlements, credited to their respective demat accounts by way of an off-market transfer through a depository participant. The Rights Entitlements can be transferred in dematerialised form only.

Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat accounts of the Renouncees on or prior to the Issue Closing Date to enable Renouncees to subscribe to the Equity Shares in the Issue.

The Shareholders holding the Rights Entitlements who desire to transfer their Rights Entitlements will have to do so through their depository participant by issuing a delivery instruction slip quoting the ISIN INE820Y20021, the details of the buyer and the details of the Rights Entitlements they intend to transfer. The buyer of the Rights Entitlements (unless already having given a standing receipt instruction) has to issue a receipt instruction slip to their depository participant. The Shareholders can transfer Rights Entitlements only to the extent of Rights Entitlements available in their demat account.

The instructions for transfer of Rights Entitlements can be issued during the working hours of the depository participants. The detailed rules for transfer of Rights Entitlements through off-market transfer shall be as specified by the NSDL and CDSL from time to time.

**INVESTORS TO KINDLY NOTE THAT AFTER PURCHASING THE RIGHTS ENTITLEMENTS (RE) THROUGH ON MARKET RENUNCIATION / OFF MARKET RENUNCIATION, AN APPLICATION HAS TO BE MADE FOR SUBSCRIBING THE SHARES OFFERED UNDER RIGHTS ISSUE. IF NO APPLICATION IS MADE BY THE PURCHASER OF RES ON OR BEFORE ISSUE CLOSING DATE, THEN SUCH RES WILL GET LAPSED AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE. NO SHARES FOR SUCH LAPSED RE WILL BE CREDITED, EVEN IF SUCH RE WERE PURCHASED FROM MARKET AND PURCHASER WILL LOSE THE AMOUNT PAID TO ACQUIRE THE RE. PERSONS WHO HAVE BOUGHT RIGHTS ENTITLEMENTS, SHALL REQUIRE TO MAKE AN APPLICATION AND APPLY FOR SHARES OFFERED UNDER RIGHTS ISSUE, IF THEY WANT TO SUBSCRIBE TO THE SHARES OFFERED UNDER RIGHTS ISSUE.**

**Fractional Entitlements**  
The Equity Shares are being offered on a rights basis to existing Eligible Equity Shareholders in the ratio of 1 (One) Equity Share for every 1 (One) Equity Share held as on the Record Date. As per SEBI Rights Issue Circulars, the fractional entitlements are to be ignored. In terms of present ratio, there will no fractional shares.

**FOR PROCEDURE OF APPLICATION BY SHAREHOLDERS WHO HAVE PURCHASED THE RIGHT ENTITLEMENT THROUGH ON MARKET RENUNCIATION / OFF MARKET RENUNCIATION, PLEASE REFER TO THE HEADING TITLED "PROCEDURE FOR APPLICATION THROUGH THE ASBA PROCESS" ON PAGE 118 OF THE LETTER OF OFFER.**

**LISTING AND TRADING OF THE RIGHTS EQUITY SHARES TO BE ISSUED PURSUANT TO THE ISSUE:** The existing Equity Shares are listed and traded on NSE (Scrip Code: AJOONI) under the ISIN: INE820Y01021. The Equity Shares shall be credited to a temporary ISIN which will be frozen until the receipt of the final listing/trading approvals from the Stock Exchange. Upon receipt of such listing and trading approvals, the Equity Shares shall be debited from such temporary ISIN and credited to the new ISIN for the Equity Shares and thereafter be available for trading and the temporary ISIN shall be permanently deactivated in the depository system of CDSL and NSDL.

**DISCLAIMER CLAUSE OF SEBI:** The Draft Letter of Offer has not been filed with SEBI in terms of SEBI ICDR Regulations as the size is below Rs. 5,000.00 lakhs. The present Issue being of less than Rs. 5,000 lakhs, our Company is in compliance with first proviso to Regulation 3 of the SEBI ICDR Regulations and our Company shall file the copy of the Letter of Offer prepared in accordance with the SEBI ICDR Regulations with SEBI for information and dissemination on the website of SEBI i.e. [www.sebi.gov.in](http://www.sebi.gov.in).

**DISCLAIMER CLAUSE OF NSE:** It is to be distinctly understood that the aforesaid permission given by NSE should not in any way be deemed or construed that the Letter of offer has been cleared or approved by NSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of the Letter of offer; nor does it warrant that this Issuer's securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer. The Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of NSE" beginning on page 110 of the LOF.

**DISPATCH AND AVAILABILITY OF ISSUE MATERIALS:** In accordance with the SEBI ICDR Regulations, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent/ dispatched only to the Eligible Equity Shareholders who have provided Indian address. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Abridged Letter of Offer, the Application Form, the Rights Entitlement Letter and other Issue material will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Further, this Letter of Offer will be sent/ dispatched to the Eligible Equity Shareholders who have provided Indian address and who have made a request in this regard. In case such Eligible Equity Shareholders have provided their valid e-mail address, the Letter of Offer will be sent only to their valid e-mail address and in case such Eligible Equity Shareholders have not provided their e-mail address, then the Letter of Offer will be dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

Shareholders can access this Letter of Offer, the Abridged Letter of Offer and the Application Forms (provided that the Eligible Equity Shareholder is eligible to subscribe for the Equity Shares under applicable laws) on the websites of:

- Our Company at [www.ajoonibiotech.com](http://www.ajoonibiotech.com).
- The Registrar at [www.cameoindia.com/https://rights.cameoindia.com/ajooni1](http://www.cameoindia.com/https://rights.cameoindia.com/ajooni1)
- The Stock Exchange at [www.nseindia.com](http://www.nseindia.com)

Eligible Equity Shareholders can also obtain the details of their respective Rights Entitlements from the website of the Registrar (i.e., **Cameo Corporate Services Ltd.** at [www.cameoindia.com/https://rights.cameoindia.com/ajooni1](http://www.cameoindia.com/https://rights.cameoindia.com/ajooni1)) by entering their DP ID and Client ID or Folio Number (for Eligible Equity Shareholders who hold Equity Shares in physical form as on Record Date) and PAN. The link for the same shall also be available on the website of our Company (i.e. [www.ajoonibiotech.com](http://www.ajoonibiotech.com)).

**BANKERS TO THE ISSUE: AXIS BANK LIMITED**  
**MONITORING AGENCY:** Not Applicable

**FOR RISK FACTORS AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER AND ALOF OTHER IMPORTANT LINKS AND HELPLINE.** The Investors can visit following links for the below-mentioned purposes:

- Frequently asked questions and online/ electronic dedicated Shareholders helpdesk for guidance on the Application process and resolution of difficulties faced by the Shareholders: [www.cameoindia.com/https://rights.cameoindia.com/ajooni1](http://www.cameoindia.com/https://rights.cameoindia.com/ajooni1)
- Update of Indian address/ e-mail address/ phone or mobile number in the records maintained by the Registrar or our Company: [www.cameoindia.com/https://rights.cameoindia.com/ajooni1](http://www.cameoindia.com/https://rights.cameoindia.com/ajooni1)
- Update of demat account details by Eligible Equity Shareholders holding shares in physical form: [www.cameoindia.com/https://rights.cameoindia.com/ajooni1](http://www.cameoindia.com/https://rights.cameoindia.com/ajooni1)
- Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders: [rights@cameoindia.com](mailto:rights@cameoindia.com)

REGISTRAR TO THE ISSUE	
	<b>CAMEO CORPORATE SERVICES LTD.</b> Subramanian Building, 1 Club House Road, Chennai 600 002. Tel No.: +044-40020700 (5 lines) E-mail ID: <a href="mailto:rights@cameoindia.com">rights@cameoindia.com</a> Investor Grievance Email: <a href="mailto:investor@cameoindia.com">investor@cameoindia.com</a> Website: <a href="http://www.cameoindia.com/https://rights.cameoindia.com/ajooni1">www.cameoindia.com/https://rights.cameoindia.com/ajooni1</a> Contact Person: Ms. K. Sreepriya SEBI Registration No: INR000003753

COMPANY SECRETARY AND COMPLIANCE OFFICER	
<b>Mrs. Swati Vijan</b>	
D-118, Industrial Area, Phase-7, Mohali Punjab - 160055	
Tel: + 0172-5020762, Email: <a href="mailto:cs@ajoonibiotech.com">cs@ajoonibiotech.com</a> , Website: <a href="http://www.ajoonibiotech.com">www.ajoonibiotech.com</a>	

Investors may contact the Registrar to the Issue or the Company Secretary and Compliance Officer for any pre- Issue/ post-Issue related matters. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the applicant, number of Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the CAF, or the plain paper application, as the case may be, was submitted by the ASBA Investors.

### CORRIGENDUM TO THE LETTER OF OFFER DATED 07<sup>th</sup> MAY, 2024

The Eligible Equity Shareholders are requested to note that the Right Issue has been approved by the Board of Directors of the Company in its meeting held on 14<sup>th</sup> October, 2023 and subsequent Board meeting held on 27<sup>th</sup> April, 2024.

- Accordingly, on page 39 of the Letter of Offer in Section IV - INTRODUCTION THE ISSUE under head "Authority for the Issue" shall be read as: The Equity Shares in the present issue are being offered pursuant to a resolution passed by our Board at its meeting held on 14<sup>th</sup> October, 2023 and subsequent meeting held on 27<sup>th</sup> April, 2024 in accordance with the provisions of the Companies Act.
- On page 52 of the Letter of Offer in Section IV - CAPITAL STRUCTURE shall be read as: The Issue has been authorized by a resolution of our Board passed at its meeting held on 14<sup>th</sup> October, 2023, and subsequent meeting held on 27<sup>th</sup> April, 2024 pursuant to Section 62 of the Companies Act, 2013.
- On page 108 of the Letter of Offer in Section VII - OTHER REGULATORY AND STATUTORY DISCLOSURES under head "Authority for the Issue" shall be read as: The Issue has been authorized by a resolution of our Board passed at its meeting held on 14<sup>th</sup> October, 2023, and subsequent meeting held on 27<sup>th</sup> April, 2024 pursuant to Section 62(1)(a) and other applicable provisions of the Companies Act, 2013.
- On page 145 of the Letter of Offer in Section IX - OTHER INFORMATION MATERIAL CONTRACTS AND DOCUMENTS FOR INSPECTION under head "(B) Documents for Inspection" shall be read as: Copy of the resolution of the Board of Directors under Section 62 of the Companies Act passed in its meeting dated 14<sup>th</sup> October, 2023 and subsequent meeting held on 27<sup>th</sup> April, 2024 authorizing the Issue.